Nav: Home

Towards better anti-cancer drugs

January 28, 2020

Most cancers are caused by a large variety of factors that vary from one person to another. To unravel this complexity, genes that contribute to the development of a respective cancer must be identified. Such genes are called oncogenes. A good example of an oncogene is CDK8: Cyclin-dependent kinase 8. Misregulated CDK8 is an important factor in the development of colon, breast and skin cancer. Hence, in recent years considerable efforts have been undertaken to develop drugs that specifically target CDK8 and that do not affect other molecules that are closely related to CDK8, but are essential for the survival of human cells. A research team at the University of Bayreuth led by biochemist Dr. Claus-D. Kuhn has now discovered how CDK8 is activated in healthy humans. The research results are published in the journal 'Proceedings of the National Academy of Sciences U.S.A.'. Apart from novel basic biochemical insights, the presented results suggest a new method by which CDK8-specific inhibitors could be developed in future.

MED12 binds and activates CDK8

The research team was mainly interested in how the oncogene CDK8 is activated in healthy cells. "One important aspect is that CDK8 does not occur in our cells as an individual molecule, but always in a complex with three partners. As part of this complex, CDK8 has completely different properties, which is why it is essential to investigate CDK8 as part of this complex", explains the first author of the study, the Bayreuth graduate student Felix Klatt. Using structural biochemistry - coupled with systems biology - the research team deciphered how CDK8 is activated by two of the three partners, Cyclin C and MED12. They demonstrated that just a tiny part of MED12 is responsible for activating CDK8. Due to its structure, the Bayreuth scientists named this part 'MED12 activation helix'.

The 'MED12 activation helix' is often mutated in tumours

"After we discovered the 'MED12 activation helix', we were very surprised to find a large number of mutations associated with uterine fibroids, breast cancer and chronic lymphatic leukemia in this very area", reports Dr. Claus-D. Kuhn, head of the Bayreuth research team 'Gene Regulation by Non-coding RNA', which is part of the Elite Network of Bavaria. "To be honest, the extent of agreement between our basic biochemical research and the sequence analysis of human tumours was unexpected." Through subsequent biochemical experiments, his team was able to show that the mutations do not lead to a destabilization of the CDK8-containing complex, as previously suspected. Rather, there is a spatial rearrangement of the 'MED12 activation helix' within the complex, which leads to an abnormally reduced activity of CDK8 - a condition that most likely contributes to tumor development.

Hope for new CDK8-specific drugs

Binding of MED12 to CDK8 not only changes its activity, it also changes the active site of the enzyme CDK8. (By way of explanation: CDK8 is a so-called kinase, i.e. it modifies various target molecules with phosphate groups that are important for the cell's gene reading machinery). As Dr. Claus-D. Kuhn's research group was able to show, this structural change leads to a situation in which so-called type II kinase inhibitors no longer bind effectively to CDK8 and inhibit it. "Conversely, this means that all future attempts to inhibit CDK8 must at least focus on triple complexes of CDK8, Cyclin C and MED12. If, as has happened in the past, inhibitors are developed only against CDK8 in complex with Cyclin C, the resulting compounds are very likely ineffective against CDK8 in human cells", concludes Dr. Claus-D. Kuhn.
-end-
Contact:

Dr. Claus-D. Kuhn
'Head of the Research group 'Gene Regulation by Non-coding RNA'
Elite Network Bavaria and University of Bayreuth
Universitätsstraße 30 / NW I
Phone: +49 (0) 921 / 55-4356; mobile: +49 (0) 173 / 468 60 37
E-Mail: claus.kuhn@uni-bayreuth.de
http://www.kuhnlab.uni-bayreuth.de

Universität Bayreuth

Related Oncogene Articles:

CNIO researchers develop an effective strategy against KRAS mutant lung tumors in mice
Researchers achieved complete remission of 25% of lung tumours caused by the KRAS oncogene in mice by inactivating CDK4 and RAF1, two genes that act at different levels in the signalling pathway of this oncogene.
Scientists ID gene responsible for deadly glioblastoma
The discovery of the oncogene responsible for glioblastoma could be the brain cancer's Achilles' heel, one researcher says.
Experimental drug combination shows potential for triple-negative breast cancer
Researchers from Vanderbilt-Ingram Cancer Center discovered a role for MYCN in triple-negative breast cancer (TNBC), a particularly aggressive form of the disease, and identified a potential intervention for further clinical investigation.
Researchers identify new roles for common oncogene MYC
Cancer researchers have discovered surprising new functions for a protein called MYC, a powerful oncogene that is estimated to drive the development of almost half a million new cancer cases in the US every year.
CNIO participates in a study identifying a novel oncogene for most common types of blood cancer
The study shows that tumour suppressor hnRNP K can lead to cancer.
Virus- and oncogene-free reprogramming method for the production of iPSCs published in the journal
Regenerative Medicine is delighted to publish open access original research demonstrating the first virus- and oncogene-free induced pluripotent stem cell (iPSC) technology to produce safer pluripotent stem cells from cord blood and peripheral blood.
Discovery of a new tumor suppressor previously thought to be an oncogene
A gene that has for decades been considered a tumor promoter, the PLK1 gene, can also perform the exact opposite function: halting the development of cancer.
The role of 'extra' DNA in cancer evolution and therapy resistance
Researchers tracked genomic alterations detected in patient samples during tumor cell evolution in culture, in patient-derived xenograft (PDX) mouse models from the cultures, as well as before and after treatment in patients.
Drug combination shows benefit in RAS-driven cancers
Dana-Farber Cancer Institute scientists report a number of patients in a small study with RAS-driven lung, ovarian, and thyroid cancers got long-term clinical benefit from a combination of two drugs that targeted molecular pathways controlled by the RAS gene.
Discovery of a new gene critical in the development of lung and pancreatic cancers
Researchers at the Center for Applied Medical Research (CIMA) of the University of Navarra (Spain) have identified a critical gene, FOSL1, in the development of lung and pancreatic cancer.
More Oncogene News and Oncogene Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Debbie Millman: Designing Our Lives
From prehistoric cave art to today's social media feeds, to design is to be human. This hour, designer Debbie Millman guides us through a world made and remade–and helps us design our own paths.
Now Playing: Science for the People

#574 State of the Heart
This week we focus on heart disease, heart failure, what blood pressure is and why it's bad when it's high. Host Rachelle Saunders talks with physician, clinical researcher, and writer Haider Warraich about his book "State of the Heart: Exploring the History, Science, and Future of Cardiac Disease" and the ails of our hearts.
Now Playing: Radiolab

Falling
There are so many ways to fall–in love, asleep, even flat on your face. This hour, Radiolab dives into stories of great falls.  We jump into a black hole, take a trip over Niagara Falls, upend some myths about falling cats, and plunge into our favorite songs about falling. Support Radiolab by becoming a member today at Radiolab.org/donate.